We have 3 of 101 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Experimental and computational findings identify compound 17 as a promising and mechanistically well‐characterized VEGFR‐2 inhibitor, warranting further in vivo investigation.
In silico ADME profiling demonstrated promising pharmacokinetic behavior, characterized by robust gastrointestinal absorption and excellent predicted blood–brain barrier penetration, supporting the potential of these derivatives as promising multifunctional candidates for the development of anti‐Alzheimer agents.
Findings identify compound 7e as a promising VEGFR-2-targeted anticancer lead with strong enzymatic inhibition, potent cytotoxicity, and a well-supported mechanistic profile integrating experimental and computational evidence.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
